Similarly, the Trp53 R172H allele used in this study was chosen for pragmatic reasons rather than its prevalence in high‐risk endometrial cancer (6% of oncogenic TP53 point mutations in high‐risk EC in the TCGA studies) and it will be of interest to examine the effects of orthologues of more common mutations such as TP53 R273H (14% of oncogenic TP53 point mutations in TCGA). This evidence concerns the gene TP53 and endometrial cancer.